Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Elobixibat for Chronic Constipation in Patients With Heart Failure
Circulation Reports · 08.03.2024 · 6 (3) · 55-63
DOI: 10.1253/circrep.cr-23-0099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation Reports, erschienen am 08.03.2024. Verfasst von Koichiro Fujisue und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University Kumamoto Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Neither the efficacy nor safety of elobixibat has been investigated in the treatment of chronic constipation in patients with heart failure (HF). Methods and Results: In this prospective, single-center, single-arm study elobixibat (10 mg/day) was administered for 12 weeks to 18 HF patients with chronic constipation defined according to the Rome IV criteria. Spontaneous bowel movement (SBM), stool consistency as measured by the Bristol Stool Form Scale, and degree of straining during defecation were recorded. In addition, biomarkers, blood pressure (BP) measured by ambulatory monitoring, and adverse events were assessed. Although there was no significant difference, the frequency of SBM increased by 2.0/week from baseline to Week 12. Both the degree of straining during defecation and low-density lipoprotein cholesterol (LDL-C) levels were significantly decreased at Week 12 (straining, -0.79 [95% confidence interval (CI), -1.40 to -0.17]; LDL-C, -10.4 mg/dL [95% CI, -17.9 to -2.9]). Although not significant, the difference in BP before and after defecation tended to decrease from baseline by approximately 10 mmHg at Week 12. Serious adverse events were not observed.
Conclusions
Elobixibat reduced the degree of straining during defecation, and improved the lipid profile in HF patients with chronic constipation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University Kumamoto Japan.
- Miyazaki Medical Association Hospital Miyazaki Japan.
- Department of Cardiology, Saitama Medical University International Medical Center Hidaka Japan.
Zitieren
APA
Fujisue, K., Ito, M., Matsuzawa, Y., Arima, Y., Takashio, S., Sueta, D., Araki, S., Hanatani, S., Yamanaga, K., Yamamoto, M., Kaneko, S., Yamamoto, E., Matsushita, K., Soejima, H., & Tsujita, K. (2024). Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Elobixibat for Chronic Constipation in Patients With Heart Failure. Circulation Reports, 6(3), 55-63. https://doi.org/10.1253/circrep.cr-23-0099
Vancouver
Fujisue K, Ito M, Matsuzawa Y, Arima Y, Takashio S, Sueta D, et al. Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Elobixibat for Chronic Constipation in Patients With Heart Failure. Circulation Reports. 2024;6(3):55-63. doi:10.1253/circrep.cr-23-0099
BibTeX
@article{Fujisue2024,
author = {Fujisue, Koichiro and Ito, Miwa and Matsuzawa, Yasushi and Arima, Yuichiro and Takashio, Seiji and Sueta, Daisuke and Araki, Satoshi and Hanatani, Shinsuke and Yamanaga, Kenshi and Yamamoto, Masahiro and Kaneko, Shozo and Yamamoto, Eiichiro and Matsushita, Kenichi and Soejima, Hirofumi and Tsujita, Kenichi},
title = {Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Elobixibat for Chronic Constipation in Patients With Heart Failure},
journal = {Circulation Reports},
year = {2024},
volume = {6},
number = {3},
pages = {55--63},
doi = {10.1253/circrep.cr-23-0099}
}
EUVIMED